Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) insider Jennifer Michaelson sold 4,000 shares of the stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $13.30, for a total transaction of $53,200.00. Following the transaction, the insider now owns 53,031 shares in the company, valued at $705,312.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jennifer Michaelson also recently made the following trade(s):

• On Tuesday, September 27th, Jennifer Michaelson sold 4,000 shares of Cullinan Oncology stock. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00.

Cullinan Oncology Stock Down 1.4 %

Shares of CGEM opened at $12.26 on Friday. The company has a market cap of $559.20 million, a price-to-earnings ratio of 5.52 and a beta of -0.09. Cullinan Oncology, Inc. has a twelve month low of $7.30 and a twelve month high of $18.46. The company has a 50 day moving average of $12.61 and a two-hundred day moving average of $12.85.

Institutional Investors Weigh In On Cullinan Oncology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rock Springs Capital Management LP lifted its stake in shares of Cullinan Oncology by 1.0% during the first quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company's stock worth $6,832,000 after buying an additional 6,500 shares during the period. Rubric Capital Management LP lifted its stake in shares of Cullinan Oncology by 88.2% during the third quarter. Rubric Capital Management LP now owns 559,737 shares of the company's stock worth $7,176,000 after buying an additional 262,390 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Cullinan Oncology during the third quarter worth $538,000. Nisa Investment Advisors LLC lifted its stake in shares of Cullinan Oncology by 24.0% during the third quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company's stock worth $222,000 after buying an additional 3,341 shares during the period. Finally, Silverarc Capital Management LLC lifted its stake in shares of Cullinan Oncology by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company's stock worth $2,879,000 after buying an additional 11,465 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, BTIG Research initiated coverage on shares of Cullinan Oncology in a research note on Monday, November 21st. They issued a "buy" rating for the company.

Cullinan Oncology Company Profile

(Get Rating)

Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.

See Also

• Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
• Ford Revving Up Production Of EV Power Units At U.K. Plant
• Are the Short Sellers Still Right About Mullen Automotive stock?
• La-Z-Boy Reclines To More Comfortable Levels
• Is Apple Going To Rally Into Year End?
• Is The Recovery Rally Here For SoFi?

Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.